On September 10, 2020, the Comprehensive Pharmaceutical R&D Strength Rankings in China for 2020 (including the general list, chemical medicine list, traditional Chinese medicine list, biological medicine list, CRO list, and CDMO list), which has attracted much attention from the industry, was released, listing the backbones of the pharmaceutical industry and innovation-leading enterprises. Among them, Kintor Pharmaceutical Limited was listed on the TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020, and was also selected to enter the most important sub-list "TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020", which not only represents the pharmaceutical industry's pinnacle R&D strength in 2019, but also plays a leading role in the industry reform.

The Company’s entry into the double lists represents the industry's high recognition of its performance. The Company will continue to focus on its core product pipelines, increase R&D investment, steadily advance the progress of its R&D projects, and continue to improve R&D innovation capabilities and R&D industrialization platform construction.

TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020

TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020